Cold Agglutinins by Meny, Geralyn M.
For more than 20 years, the AABB and the American Red Cross
(ARC) have hosted the Immunohematology Reference Laboratory
(IRL) Conference in mid-spring. Initially the conference was jointly
hosted by the two organizations; it has since been hosted
alternately, with each organization choosing the host city and
planning the conference. The conference has been held in various
cities throughout the United States, including Atlanta, Chicago, Las
Vegas, New Orleans, Memphis, and this year, Orlando.The 2007 IRL
Conference will be hosted by the AABB and held in Albuquerque,
New Mexico, the weekend of March 27 to 29, 2007.
The conference begins on Friday afternoon with proctor-led case
studies discussing advanced immunohematologic investigations,
followed by a welcoming reception that promotes connecting and
networking with fellow technologists and physicians from around
the country and, typically, Canada. Saturday begins with breakfast
followed by speaker presentations on various serologic, technical,
clinical, administrative, quality, and regulatory issues that affect
today’s reference laboratories. These presentations extend until late
afternoon with scheduled breaks and a provided lunch. The
presentations continue on Sunday with the conference ending at
noon. Attendees are encouraged to bring posters for viewing and
those that do have the opportunity to present the information to all.
Following are summaries of the presentations given at the 2006 IRL
conference that was hosted by the ARC from April 28 to 30 in
Orlando, Florida.
Reference Laboratory’s Joys and Woes—
30 Years (1975–2005) 
I had been working for 8 years in blood banking at
War Memorial Blood Bank (now known as Memorial
Blood Center) in Minneapolis, Minnesota, when I came
to Gamma Biologicals, Inc., in Houston,Texas, to work
in the consultations service. I began as the supervisor
of consultation on August 1, 1975, became the director
of consultation and education in 1990, and was named
the vice president of consultation and education
services in 1996, a position I held until 1998 when I
joined Immucor as the vice president of reference and
education services.
There are several elements essential to having a
successful immunohematology reference laboratory
for RBC serology. The first element is to have staff that
is competent, dedicated, enthusiastic, and eager and
willing to investigate all types of samples,whether they
contain cold- or warm-reactive autoantibodies or a
combination of the two, mixtures of alloantibodies,
antibodies directed at low- or high-incidence antigens,
or even the mundane Lewis, P1, or Bg antibodies. The
second element is to have a facility where management
is willing to support the many, and sometimes lengthy,
investigations associated with resolving complicated
serologic problems. Another element is to have the
resources of unusual and rare RBCs and antibodies to
perform special investigative studies. These are
obtained by the collecting and sharing of samples by
immunohematologists around the world. The SCARF
program (organized by John Moulds) and other
exchange programs have certainly helped to
accomplish this. In addition, very importantly, a
reference laboratory needs blood bankers in
transfusion services, prenatal testing laboratories,
donor centers, and even reagent manufacturing
facilities who are willing to take the time to send
samples for further studies. They are the ones who
have the patients whose lives can be saved by
providing the best possible blood for transfusion. They
also have access to families and donors that could aid
in furthering our knowledge of blood groups. And, last
but not least, a key element to the success of an
immunohematology reference laboratory is education.
I was very fortunate to be able to attend meetings and
seminars worldwide, as well as to be able to give talks
on the special cases we investigated and the new
methodologies and technologies introduced to blood
banking that helped us to resolve the unusual cases.
There are many joys in working in an
immunohematology reference laboratory. However,
sometimes there are woes, such as regulations,
assessments, validations, SOPs, corrective actions, etc. I
have learned over the years to deal with these woes as
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bad. I am not always good at taking my own advice,but
I do like to give it!!!
It has been a wonderful 30 years and I have many
to thank for the support I have had in my career: from
my mentors, the facilities that employed me, and the
more than 20 staff members who worked with me at
Gamma and Immucor and,before that, at War Memorial
Blood Bank, Chadron Community Hospital in Chadron,
Nebraska, and St. John’s McNamara Hospital in Rapid
City, South Dakota. Also, I extend a special thanks to
the blood bank friends and customers who shared
samples with our immunohematology reference
laboratory. I wish all of you the best in your careers in
the future and hope that there will always be those
who have the desire and dedication to work on special
serologic problems for the best patient care we can
give.
Marilyn K. (Grandstaff) Moulds, MT(ASCP)SBB, Vice
President Education, ImmucorGamma, Norcross,
Georgia/Houston, Texas.
Serologic Results to Diagnostic
Interpretation 
Beyond the tests associated with antibody
identification studies routinely performed in an
immunohematology reference laboratory (IRL) are
serologic tests that can lead to diagnosis. Serologic
results alone, however, are not diagnostic. Their
significance must be reviewed in conjunction with the
patient’s clinical condition. The following reviews
serologic testing the author feels has a direct impact in
diagnosis as well as comments on several requested
tests that this author believes have limited value.
Detection of Mixed-Field Agglutination
Detecting mixed-field agglutination (2-cell
populations) when performing ABO and D typings can
be used to assess engraftment of marrow in a
transplant recipient. Likewise, detecting mixed field in
antigen typing can be used as an aid in assessing the
survival of transfused RBCs.
Direct Antiglobulin Test
One of the most useful tests in the investigation of
hemolysis is the DAT. Careful analysis of DAT results, in
conjunction with the evaluation of serum reactivity,
can lead to the diagnosis of warm autoimmune
hemolytic anemia, cold agglutinin disease, and
paroxysmal cold hemoglobinuria and can allow the
physician to plan a course of treatment. Additional
testing can be performed to evaluate patients with so-
called DAT-negative hemolytic anemia in an attempt to
detect an antigen-antibody reaction. This type of
information is valuable to the patient’s physician
because it can help confirm hemolysis is immune-
mediated.
An area in which serologic testing can be
misleading is the detection of newly forming
antibodies in patients that have been recently
transfused. A positive DAT posttransfusion with
identification of a new antibody 7 to 14 days after
transfusion alerts the laboratory to a possible delayed
transfusion reaction. Clinical evidence of hemolysis is
the key to differentiate a delayed hemolytic transfusion
reaction from a delayed serologic transfusion reaction.
Elution 
Elution procedures are performed to determine the
specificity of the antibody coating the patient’s RBCs.
Eluates can confirm alloantibody specificity identified
in the patient’s serum. In rare cases, newly forming
antibody can only be found coating the transfused
RBCs in a recently transfused patient. A negative eluate
in a patient with a strongly positive DAT (4+) may
indicate that the patient has a drug-dependent
antibody. Further review of the patient’s clinical
course and medication history may indicate the patient
is experiencing drug-induced immune hemolytic
anemia. Drug studies to look for the presence of drug-
dependent antibodies will confirm this diagnosis.
Lectin Testing
Testing samples from infants and children with a
panel of lectins may be valuable in detecting T-activated
polyagglutinable RBCs, particularly in infants with a
bacterial infection. However, routinely screening for
polyagglutination in newborns with a diagnosis of
necrotizing enterocolitis (NEC), for example, is
generally not performed. RBCs from normal, healthy
infants can show T activation and infants with NEC and
possessing T-activated RBCs may show no hemolysis.
Most experts believe that testing for polyagglutination
should be selectively performed when the neonate has
received RBCs or plasma products and has
demonstrated hemolysis or an unexplained lack of rise
in posttransfusion Hb.
There are rare examples of immune-mediated
hemolysis in children because of T-activated RBCs and
the child’s own anti-T. The exact mechanism of
hemolysis is not fully understood.
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Ii Antigen Typing
Occasionally the IRL is asked to perform Ii antigen
typing on a child. This is generally requested when a
physician suspects stressed hematopoiesis. The i
antigen is characteristic of fetal erythropoiesis and may
be increased in cases of hereditary erythroblastic
multinuclearity with a positive acidified serum
(HEMPAS), aplastic anemia, and myeloblastic
erythropoiesis, for example. There are several issues to
consider before performing this typing. The first issue
is that antisera are in limited supply. The second issue
is that, since the level of I antigen expression increases
and i antigen expression decreases with age, samples
from children about the same age as the patient to be
tested should be used as a control. Also, this testing can
only be performed if the child has not been transfused
within the past 3 to 4 months. Lastly, there are other
tests that will provide more useful diagnostic results
than determining the Ii antigen status.
ABO Titration in Transplant Patients
IRLs are being asked to assist transplant programs
by performing anti-A and anti-B titration studies for
ABO-incompatible kidney transplants and for ABO-
incompatible heart transplants in infants.
In ABO-incompatible kidney transplants, the
recipient is usually group O and the kidney donor is
group A2 or B. The procedure accepted by the United
Network for Organ Sharing for ABO titration is peculiar
to immunohematologists. Patient serum is treated with
DTT to destroy IgM anti-A or anti-B and dilutions of
patient serum are tested against pooled group A or B
RBCs by incubating at room temperature for 10
minutes. If the titer is less than 8, the patient is
considered able to receive a kidney from a group A2 or
B donor. ABO titers are performed periodically before
transplant, immediately before transplant, and
immediately posttransplant. If the titer increases
following transplant, a plasma exchange may be
performed to reduce the ABO-antibody titer.
The ABO titration performed to monitor infants
less than 1 year old consists of diluting the patient’s
serum in saline, preparing doubling dilutions, adding
known group A or B RBCs, and incubating the mixture
at room temperature for 30 to 60 minutes.
Interestingly, ABO antibodies often detected in infants
are passively acquired from transfusion once maternal
antibody clears.
Although more and more is being discovered about
blood groups at the molecular and biochemical level,
relatively simple serologic tests to detect antigen-
antibody reactions continue to play a major role in
diagnosis and monitoring of a patient’s disease.
However, a serologic test result alone must always be
correlated with the patient’s clinical condition to
provide the utmost value to the patient’s physician.
Susan T. Johnson, MSTM, MT(ASCP)SBB, Manager,
Immunohematology Services, BloodCenter of
Wisconsin, Milwaukee, Wisconsin.
Special Notes When Using Anti-D
Monoclonal Reagents 
Commercial anti-D reagents using monoclonal
antibodies began to be widely used in the early 1990s.
Since then, differences among the reactivity of the
various reagents with unusual or rare D+ RBCs have led
to widespread discussion of the testing appropriate for
blood donors, transfusion recipients, and obstetric
patients. D+ RBCs giving varying reactions fall into the
categories of weak D, partial D including the R0
Har
phenotype,and the Crawford (ceCF),ceRT,and the DEL
(Del) phenotypes. Currently, there are several types of
anti-D reagents available, including human blend,
monoclonal/polyclonal blend, monoclonal/monoclonal
blend, and monoclonal IgM used in the gel card.
Another influence on the types of reactions observed
is the technique used: tube, microplate, slide, gel cards,
or automation, to name a few. Also, some reagents react
best with these unusual RBCs at immediate spin (IS)
and room temperature, some at IS and after incubation
at 37°C, and some only in the IAT. In addition, the
ethnic background of the person whose RBCs give
these unusual varying reactions is significant.
Weak D
The incidence of weak D has previously been
reported as 0.23 and 0.5 percent in Europe and 3
percent in the United States. These studies were
performed before the introduction of monoclonal anti-
D reagents. A study published in 20051 reported on the
incidence of weak D blood donors typed as D+ by
Olympus PK7200 as 0.4 percent (4 of 1005 donors).
Partial D
Judd et al. also reported in 20052 on the reactivity
of FDA-approved anti-D reagents with partial D+ RBCs.
They compared reactions in tube tests using anti-D
reagents from Gamma, Immucor, and Ortho and with
Ortho gel cards and found differences among
Categories DVa, DBT, and R0
Har RBCs in the various
phases of testing.
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Crawford (ceCF)
In 2003, Schlanser et al.3 reported on the Crawford
phenotype that is present in African Americans and in
two individuals from Colombia. RBCs with this unusual
phenotype react with two monoclonal/monoclonal
blend anti-D reagents but not with other anti-D
reagents.
ceRT and Del
Even more recently, there have been several reports
(a review, an editorial, and a forum)4–6 that focus on the
issue of whether RBCs of blood donors with these
phenotypes can elicit the production of anti-D in
transfusion recipients and obstetric patients and
whether we should be concerned with weak D. These
publications can be consulted for the various opinions
and other pertinent references.
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Cold Agglutinins 
As serologists know, cold agglutinins found in
normal individuals may interfere with pretransfusion
testing. Cold agglutinins are also found in individuals
with disorders including cold hemagglutinin disease
(CHD) and paroxysmal cold hemoglobinuria (PCH).
Reference laboratory serologists play a key role in
helping to distinguish the former benign type of cold
agglutinins from the latter, more clinically significant
type.
The focus of this discussion will not be on the
serologic management of cold agglutinins. Rather, it
will be on three clinically related topics: the association
of cold agglutinins with patients undergoing cardiac
surgery, with blood donors, and as critical values.
Should one be concerned with cold agglutinins in
cardiac surgery patients?  Over the last 10 to 20 years,
the number of cardiac catheterization and
percutaneous coronary intervention procedures has
continued to increase, while the number of coronary
artery bypass surgery procedures (CABG) peaked in
1997 and has since started to decline. 0.8 to 4 percent
of cardiac surgery patients have been found to have
some type of cold agglutinins. This compares with an
incidence of 1 in 41,000 to 1 in 80,000 individuals with
autoimmune hemolytic anemia (15.6% of these
individuals have CHD).
The traditional CABG permits a cardiopulmonary
bypass (CPB) machine to take over the functions of the
cardiac and pulmonary systems (i.e., to pump blood
through the body, while supplying oxygen and
removing carbon dioxide). It also permits the surgeon
to operate on a quiet, bloodless surgical field.
Techniques initiated systemic hypothermia to 28 to
32°C, while cold (~5°C) potassium cardioplegic
solutions were infused into the coronary arteries via
the aortic root. By modifying the temperature or the
manner in which cardioplegic solutions are infused,
surgeons are now able to avoid complications that
potentially may be induced by cold agglutinins.
Perhaps a more preferable way of referring to cold
agglutinins is as cold-reactive proteins. There are three
categories of cold-reactive proteins that may cause
concern in cardiac surgery patients:cryoglobulins,cold
agglutinins, and Donath-Landsteiner (DL) antibodies.
Cryoglobulins (Types I–III) are serum proteins that
reversibly precipitate in the cold. Four cases of
patients with cryoglobulinemia undergoing CPB
surgery have been reported in the literature. The
outcomes of these cases were all successful even
though the techniques used varied. Some used plasma
exchange to reduce the patients’ cryocrit while others
used temperature modifications in systemic or
cardioplegic solutions.
Cold agglutinins are antibodies that typically bind
to RBC antigens and cause agglutination and
complement fixation over a particular temperature
range. They are disturbing to the cardiac surgery
patient (and surgeon) for their potential to cause
agglutination within the circuit or within coronary
arteries that may result in hemolysis or organ damage
secondary to agglutination or complement-mediated
RBC destruction. Several case reports of hemolysis
associated with CPB, as well as ways to avoid
complications, have been published both in
transfusion-medicine and cardiovascular-surgery
literature. All serologists are encouraged to review
these papers critically if requested to prescreen cardiac
surgery patients for cold agglutinins.
The DL antibody is a biphasic IgG hemolysin that is
classically associated with PCH. There is only one
reported case in the literature of a patient with the DL
antibody undergoing cardiac surgery.
Certain strategies may be considered when
managing CPB patients with cold-reactive proteins. If
cold-reactive proteins are detected before surgery, the
surgical procedure can be modified to maintain
normothermic systemic circulation and a crystalloid
cardioplegic solution (rather than a blood-based
cardioplegic solution) can be used. Plasma exchange
may be helpful, for example, in cryoglobulinemia to
reduce the cryocrit or in other cases of IgM-only
antibodies. Patients with documented CHD may
present special concerns. If cold-reactive proteins are
not detected before surgery, the surgeon should
observe for agglutination during cooling of the
cardioplegic unit. If detected at that time, both
systemic hypothermia and cold blood or cardioplegia
should be avoided.
Individuals can be healthy enough to donate a unit
of blood (allogeneic or autologous) and evidence of
cold agglutinins may be found in these units, either
grossly or microscopically. Units with gross evidence
of cold agglutinins must be detected prior to issue. The
use of digital imaging visual technology may prove
helpful in the near future for communicating
information between individuals in differerent facilities
(e.g., does this unit have a clot or cold agglutinin?) and
for education.
The College of American Pathologists transfusion
medicine checklist now contains the following Phase II
requirement:“Are critical values established for certain
tests that are important for prompt patient
management decisions?” There may be certain critical
situations where discussion between the laboratory
and the ordering physician should take place with
regard to cold agglutinins; these may include evaluating
a patient for autoimmune hemolytic anemia, resolving
an ABO discrepancy, and detecting cold alloantibodies
that one considers clinically significant or that delay
the procurement of blood.
Geralyn M. Meny, MD, Medical Director, American
Red Cross Blood Services, Penn-Jersey Region,
Philadelphia, Pennsylvania.
Polyagglutination 
Polyagglutination is still present but rarely seen
because of the use of monoclonal ABO typing
reagents. Human-based ABO reagents contained
polyagglutinins that interfered with the forward
typing of RBC samples from patients with
polyagglutinable RBCs. A basic review of polyagglu-
tination will be presented.
Polyagglutinins are considered naturally occurring
as they are most likely stimulated by normal flora found
in the intestines. There are three types of
polyagglutination: microbially induced, nonmicrobially
induced, and inherited. The microbially-induced
polyagglutination types are T, Th, Tk, Tx, VA, and
acquired B. Microbial polyagglutination is transient and
once the infection is eradicated, the polyagglutinable
state goes away. One interesting note about T
polyagglutination is that it may be a useful marker for
hemolytic-uremic syndrome. Tk polyagglutination
alters ABH, Ii, Lewis, and P1 antigens. Few cases of Th
polyagglutination have been identified. Tx
polyagglutination is also rare and is found in children
with pneumococcal infections. Acquired B is usually
found in patients with bowel disorders. The VA stands
for Vienna and these polyagglutinable RBCs have
reduced expression of the H antigen.
The nonmicrobial form of polyagglutination is Tn.
Tn is permanent and irreversible. Tn RBCs acquire a
weak A-like antigen. Tn has also been shown to be
associated with leukemia.
The inherited forms of polyagglutination are CAD,
HEMPAS,NOR,and Hemoglobin M-Hyde Park. HEMPAS
stands for hereditary erythroblastic multinuclearity
with a positive acidified serum test. HEMPAS RBCs
have increased expression of i antigen and normal to
increased I antigen expression.CAD 1,CAD 2, and CAD
3 phenotypes have been identified in which only CAD1
is considered polyagglutinable. RBCs with the
autosomally inherited NOR form of polyagglutination
were found not to react with cord sera. Polyagglu-
tinable RBCs are usually identified by their reactivity
with different lectins and with all adult ABO-
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compatible serum or plasma,and by their nonreactivity
with cord sera.
Janet Vincent, MS, SBB(ASCP), University of Texas
Medical Branch, Galveston, Texas.
Project Management 
Immunohematology reference laboratories (IRL)
provide a critical,value-added service to patients and to
the healthcare community. The IRL commonly focuses
on testing and operational issues;however, IRL staff and
supervisors often serve as agents of change as well.
Changes within the IRL, such as implementing new
techniques or preparing for computer software
upgrades, may benefit from application of project
management techniques and tools.
Project management is anchored by the project
management body of knowledge (PMBOK). The
Project Management Institute maintains the guide to
the PMBOK, which consists of 44 processes. These
processes or activities fall into one of five process
groups; initiation, planning, execution, closure, and
monitoring or control. The processes or activities can
also be grouped by knowledge area; integration, scope,
time, cost, risk, human resources, quality,
communication, and procurement. Full exploration of
the PMBOK is beyond the ability of this review, and
therefore, three selected process groups and 12
processes will be explored as an overview of project
management.
Project Planning
Project planning includes defining the scope of the
project. The scope statement should describe the work
that will be done within the boundaries of the project,
and where relevant, the work that is out of scope.
Goals, objectives, and measurements are also defined
during planning. Project goals are commonly
established on the basis of one of four elements:
schedule, cost, quality, or performance. Objectives will
address decisions, inputs, or activities that are essential
to meeting one of the project’s goals. Measurements
should be very specific and should detail how the
objective will be measured and the success target
value. Critical to measurement design is that the
measurements take place during execution of the
project; this ensures that corrective action can be taken
during the course of the project in time to bring the
project back on track. Tasks and activities for the
project work are detailed with input from subject
matter experts. Resources are assigned to each task or
activity on the basis of the required skills or abilities.
Each task or activity is evaluated for an estimated
duration and dependencies between tasks and
activities are identified. A schedule is constructed by
assigning estimated start and finish dates, starting with
constrained dates, or with a chosen project start date.
Risk planning is initiated by evaluating the scope and
schedule as well as other sources, for “things that could
go wrong.” The identified risks are evaluated for
probability of occurrence and impact on the project.
Selected risks are assigned mitigation actions. A plan
for monitoring the project is designed on the basis of
the objectives and measurements, risk plan, and other
component planning activities.
Project Execution
Project execution is the act of performing the tasks
or work associated with the project. The project plan,
containing elements described in the planning process,
becomes the road map for the project. With a well-
written plan, the project team should be able to work
the plan and appropriately respond to events that
signal an off-course project. During execution,
periodic reports and communication should take place
as well as celebration of project accomplishments.
Project Closure
During project closure, the team should review
lessons learned, that is, what went wrong and what
went well within the project. This information is
captured for sharing with other current and future
projects. Effectiveness data are collected and evaluated
during closing as well as identification of future
enhancements.
The appropriate application of project
management skills, tools, and techniques increases the
probability of project success. The extensive planning
process should cumulate in a project plan that creates
a common understanding of the project and its goals.
The project plan becomes an active road map for the
project.
Ann Church, PMP, MS-PM, CQA,CQIA(ASQ),
MT(ASCP)SBB, Project Manager, American Red Cross
Blood Services, BHQ-IRL Operational Support,
Philadelphia, Pennsylvania.
ISBT 128 for the IRL 
ISBT 128 is an international information standard
for blood, tissue, and cellular therapy products. It
defines how information can be encoded for
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transmission via different delivery mechanisms,
including linear bar codes (Code 128 symbology), two-
dimensional bar codes, radio frequency identification
tags, or electronic messaging. It is currently in use in
many countries with more countries implementing it
each year. The AABB will require U.S. blood banks to
implement the system for blood labeling by May 2008.
Data that can be encoded using the ISBT 128
information standard include the unique donation
identification number, ABO and Rh, product code,
donation type,expiration date,HLA test results (genomic
or serologic), RBC antigens, platelet antigens, CMV, IgA,
HbS, patient identification number, patient date of birth,
catalog and lot numbers of supplies, and staff
identification codes. Specifics of how the information is
encoded, as well as reference tables, can be found in the
document available from ICCBBA titled ISBT 128
Standard, Technical Specification. Databases support-
ing the encoded information are maintained by ICCBBA,
Inc., and are available on its Web site (www.iccbba.org).
Specifics on labeling in the United States may be found
in the U.S. Consensus Standard.
Of particular interest to immunohematology
reference laboratories is the ability of ISBT 128 to
encode a RBC phenotype obtained by testing for
antigens such as: A1, C, c, E, e, Cw,VS/V, K, k, Kpa, Jsa, M,
N,S, s,U,P1,Lua, Lea, Leb, Fya, Fyb, Jka, Jkb,Doa,Dob,Dia,Mia
as well as a long list of less commonly typed antigens.
By encoding information for transfer via bar codes or
electronic messaging, greater process control and
accuracy can be achieved. In addition, automated
transmission allows clear, unambiguous information to
be transferred across language barriers, supporting the
international sharing of rare blood, tissue, and cellular
therapy products.
ISBT 128 is not merely a labeling system. By
understanding and using its potential, secure
information transfer for blood, tissue, and cellular
therapy products is possible. This should lead to an
increased level of safety for patients.
Pat Distler, MS, MT(ASCP)SBB, Technical Director,
ICCBBA, Inc., York, Pennsylvania.
Lean but Not Mean: Doing More with Less in
the IRL 
Continuous process improvement can be a
valuable approach to achieve and sustain customer
satisfaction as well as process excellence. There are
many methodologies and tools for process
improvement, one of which is Lean. Though many
definitions exist for Lean, it can be described as a
comprehensive evaluation of operations to identify and
eliminate waste, decrease variation, and increase
efficiency. Central to the Lean approach is to use the
voice of the customer and evaluate processes on the
basis of what the customer views as valuable. Table 1
lists sources of waste that are relevant to the
immunohematology reference laboratory (IRL).
Lean has a “tool box” of tools that can be applied
when evaluating and improving processes. Value
stream mapping involves “walking” the process from
beginning to end with intense observation and
interviewing, as needed, to fully understand the
process. Cycle times and measurement of wait are also
included. The value stream map is evaluated for waste
and a desired state or “to be” map is drawn. Gaps
between the “as is” and “to be” are identified and
prioritized for improvement efforts. The application of
5S can yield benefits: sort (clear out clutter), set in
order (place remaining supplies or items in alignment
with process flow), shine (clean the work area),
standardize, and sustain. Other Lean tools include
streamlined physical layout, standardized work, batch-
size reduction,workplace teams,kanban,or pull system
(perform work only when customer order is placed),
and point-of-use storage.
Table 1. Examples of waste in the IRL
Source of waste IRL example
Overproduction Antigen typing of donor units for stock i.e.,
without a customer order 
Inventory Storage of excessive amounts of test tubes or
other supplies, such as blank forms 
Defects Incomplete documentation on testing
worksheets, incorrect test result, delayed result 
Over-processing Academic “for fun” testing that is performed
routinely, testing protocols beyond industry
standard of practice, antibody reconfirmation,
ABO and D testing performed after initial
sample testing
Waiting Time that elapses from sample notification to
sample receipt, from sample receipt to initiation
of testing
People underutilized Highly trained staff performing filing or other
clerical tasks, not including staff in problem
solving or improvements efforts
Motion Excessive up and down activity to obtain
reagents and supplies during testing, cell
washers located away from work stations,
reagents stored in remote sites 
Transportation Movement of sample from patient to testing
site, supplies from warehouse to laboratory,
blood products from IRL to distribution
department 
Though Lean has many benefits and opportunities,
it can fall prey to challenges that serve as obstacles to
its successful use. These challenges include the human
element; staff with a pervasive batch mentality, desire
for autonomy, resistance to change, and perspective
that “we are different; we save lives.” Other challenges
include lack of staff training in the Lean tools and
teamwork, not enough attention to voice-of-the-
customer, and conflicting needs among different
customer groups (FDA, AABB, patients, physicians,
quality department, donors, etc). Last, but not least, of
the obstacles is that Lean may not be a good fit for
every organization. If appropriately chosen and
applied, Lean can add value to the IRL through removal
of waste, creating increased efficiency that allows for
opportunities to enhance and expand service.
Ann Church, PMP, MS-PM, CQA,CQIA(ASQ),
MT(ASCP)SBB, Project Manager, American Red Cross
Blood Services, BHQ-IRL Operational Support,
Philadelphia, Pennsylvania.
D.R.U.G.S. in the Workplace
Drug-induced immune hemolytic anemia (DIIHA)
is an uncommon finding. To confirm its diagnosis,drug
testing is performed to identify drug-dependent
antibody (DDA).
Drugs most often implicated in DIIHA today are
second- and third-generation cephalosporins.
Cefotetan leads the list in reports by Arndt and Garratty
as well as in testing performed in this author’s
laboratory.1 There are many other drugs known to
cause DIIHA. Important in determining the testing
needed to detect these drug-dependent antibodies is
having knowledge of the drug’s characteristics in
laboratory testing. Some drugs, like the cephalosporins
and penicillin group, bind tightly to the RBC
membrane. Most others require that the drug be
present in a soluble form. Many nonsteroidal anti-
inflammatory drugs require drug metabolites for
detection of DDA.
Initial serologic testing normally shows the DAT to
be positive. Strength of reactivity is reported from
strong (3–4+) positive because of IgG binding to weak
positive because of complement binding only. Work
performed in this author’s laboratory has shown that
the DAT is most often strongly positive (2–4+)
regardless of the drug. Most often, the DAT is positive
because of IgG and C3, less often because of IgG only,
and least often because of only complement coating
the RBCs. The eluate is classically negative because
drug is not present in the test mixture. However, there
are several reports of eluates being disproportionately
weaker (≤2+) as compared with the strength of the
DAT (3–4+). Serum is also reported to be negative in
routine antibody detection tests for the same reason.
However, drug-independent “autoantibody” or drug
present in the patient’s circulation may cause a positive
antibody detection test without drug.
Arndt and Garratty propose dividing DDAs into
two categories, those that react with drugs bound
firmly to RBCs,called the “drug adsorption mechanism”
and those that react with drugs that do not bind firmly,
known as the “immune complex mechanism.”1
A new classification is proposed when referring to
DDAs on the basis of testing methods: those that react
with drug-treated RBCs or those reacting in presence
of drug. This classification is suggested to eliminate
confusion and controversy in using mechanisms of
drug-dependent antibody binding to categorize these
antibodies.
A careful drug history is important in the face of
significant RBC hemolysis in a patient. DIIHA should
be considered when there is serologic evidence of
warm autoimmune hemolytic anemia with a strong
positive DAT and positive IAT, or of cold agglutinin
syndrome with a strong positive DAT because of C3
and serologic testing shows a positive antibody
detection test at immediate spin. A thorough
investigation for DDA requires knowledge of the
characteristics of the putative drug to confirm the
presence of DDA.
1. Arndt PA, Leger RM, Garratty G. Serology of
antibodies to second- and third-generation
cephalosporins associated with immune hemo-
lytic anemia and/or positive direct antiglobulin
tests. Transfusion 1999;39:1239-46.
Susan T. Johnson, MSTM, MT(ASCP)SBB, Manager,
Immunohematology Services, BloodCenter of
Wisconsin, Milwaukee, Wisconsin.
Coagulation for Blood Bankers 
Most blood bankers understand ABO blood groups
and how to match a unit. Words like Kell, Kidd, RhIG,
and transfusion reactions are commonplace. They are
familiar with transfusion medicine and when to
dispense platelets, FFP, and products that can help
trauma victims or hemophiliacs. With all of that
knowledge, why do they need to add another topic to
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their plate?  They are certainly busy enough!  Well,
when the blood bank is busy, so is the coagulation
department!  So what happens when the two
departments meet and what do they have in common?
There are many concepts in each department that can
enhance the understanding of testing and benefit the
most common denominator—patient care.
Hemostasis 
Hemostasis is a system of checks and balances. It
compromises the vascular system,platelets,and a series
of enzymatic reactions that affect the coagulation
factors. When the coagulation system is activated
inappropriately, an individual will experience a bleed
or a thrombotic event.
Primary hemostasis in coagulation deals with
platelets. These small disc-shaped cells do not contain
a nucleus; their activity is controlled by their granules.
Platelets are the primary response to an injury. They
undergo a shape change from a disc to a spiny sphere.
They then adhere to the site of the vessel injury. Many
factors are required in this process, including
fibrinogen and von Willebrand factor (vW). This is
considered primary aggregation and is reversible. The
final phase is a release reaction whereby platelets
release their contents of dense and alpha granules. This
is called secondary aggregation and is irreversible.
Secondary hemostasis involves a series of
enzymatic reactions that activate the coagulation
factors, resulting in the formation of a fibrin clot. This
complex reaction includes a system of inhibitors and
activators and uses a complex mixture of relatively
unstable proteins that are difficult to purify as well as
phospholipids and calcium ions.
The Coagulation Laboratory
The coagulation laboratory evaluates secondary
hemostasis by assessing the in vitro coagulation
cascade by performing the screening tests: the
prothrombin time (PT) and the activated partial
thromboplastin time (APTT). This cascade does not
reflect clotting physiologically; however it does play a
role in the laboratory evaluation of a potential
coagulation disorder.
The PT and the APTT provide a tremendous
amount of information to the physician. They can be
performed quickly and accurately. Abnormalities of the
test results can assist the clinician in determining
preoperative status and bleeding disorders, and in
monitoring anticoagulation therapy.
Prothrombin Time
The PT test evaluates factors in the extrinsic
pathway. It uses citrate anticoagulated plasma, and
after the addition of an optimum concentration of
calcium and an excess of thromboplastin, clot
detection is measured by an automated device. The
result is reported in seconds. The PT  is exclusive for
Factor VII, but assesses other deficiencies of factors II,
V, and X, which are found in the common pathway.
Therefore, if a patient presents with a prolonged PT
and there is no other clinical abnormality or
medication, the patient is most likely Factor VII
deficient.
This test also looks at the monitoring of warfarin
therapy; excessive dosage of this anticoagulant is the
most likely reason for a prolonged result. Monitoring
anticoagulation has a variable and unpredictable
response. As a result, if the level is inadequate, the
patient may experience thrombosis and if the level is
excessive, the patient may bleed. So how does this
affect the blood bank?  Warfarin inhibits the
carboxylation of the glutamate residues of the vitamin
K-dependent factors (II, VII, IX, X, proteins C, and S),
rendering them nonfunctional and impairing fibrin
formation. Their loss of function is half-life–dependent.
Factor VII has the shortest half-life, 4 hours, while
Factor II has the longest,2 days. For example, if a factor
level is at 100 percent and it has a half-life of 4 hours,
the activity of this factor will be at 50 percent after 4
hours. Understanding this becomes important when
looking at replacement therapy as this will impair
fibrin formation. Warfarin has a half-life of 35 hours. It
can be administered for life and bleeding is a potential
risk because of the influences of diet, vitamin K
ingestion, body mass, and liver function. Eighty drugs
interfere with coumadin and blood levels are only
therapeutic 65 to 80 percent of the time. In addition,
the results of the test are affected by the instrument
and reagent system used in the laboratory. A system,
the International Normalized Ratio (INR), has been
developed to help standardize the monitoring so that
treatment can be more precise. It uses a formula that
combines the patient PT, the mean of the normal range,
and the sensitivity of the reagent as determined by the
manufacturer.
The therapeutic range of the INR is 2.0 to 3.0 for
prophylaxis and treatment of thrombosis, a pulmonary
embolism, or a myocardial infarction. A high dose
range of 2.5 to 3.5 is used for treatment of a mechanical
heart valve. (Table 1)  So how does this information
M.K. MOULDS ET AL.
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affect blood bankers?  The AABB guidelines for using
FFP are:
1. Bleeding or planned invasive or surgical
procedure and 1 or more of the following:
a. PT greater than 1.5 times the mean of the
normal range or greater than 17 seconds
b. APTT greater than 1.5 times the mean of
the normal range or greater than 49
seconds
c. Deficiency of factor II,V,VII, X, or XI
d. Massive transfusion of more than 10 units
e. Disseminated intravascular coagulation
f. Thrombotic thrombocytopenic purpura or
hemolytic-uremic syndrome
Activated Partial Thromboplastin Time
The APTT evaluates deficiencies of intrinsic factors
VIII, IX, XI, and XII. The methodology involves the
addition of a contact activator (e.g., celite, kaolin,
microsilicate, or ellagic acid) and plasma. This mixture
is incubated at 37°C, usually for 5 minutes.
Thromboplastin preparation is added and mixed.
CaCl2, is added and the result is measured in seconds.
This test is also used to monitor heparin therapy.
Heparin is an acidic mucopolysaccharide that inhibits
all of the active serine proteases (IIa, Xa, IXa, XIa, and
XIIa). It has a strong negative charge and a circulating
half-life of only a few hours. It is stable for 24 hours in
a 5% dextrose solution. Elimination is largely by the
kidney so that heparin must be used cautiously in
patients with impaired glomerular filtration. Heparin is
best administered intravenously, intermittently, or,
better, as continuous infusion in a dosage of 400 to 500
units/kg body weight/day divided into every 6-hour
dose so that 100 to 125 units/kg body weight are given
each 6 hours. (APTT target range of 60 to 85 seconds
or APTT ratio that is equivalent to a heparin level by
antifactor Xa assay of 0.3 to 0.7 units/mL). Because of
the biological variability that occurs with heparin,
there has been no ability to standardize testing.
Heparin is greatly affected by weight, is not well
absorbed by the gastrointestinal tract,and is affected by
liver function as well as by the concentration of
antithrombin that is required for binding. There is no
dose-response relationship, meaning that each patient
will react differently to a dose.
The Common Pathway
The common pathway is the part of the cascade
where the intrinsic and extrinsic pathways merge and
factors I, II, V, and X are measured. However, it is
important to know that the PT and the APTT will not
detect qualitative or quantitative platelet disorders or a
Factor XIII deficiency. Factor XIII is fibrin stabilizing
factor; this is responsible for stabilizing a soluble fibrin
monomer to form an insoluble fibrin clot. If a patient
is Factor XIII deficient, the patient will form a clot but
will not be able to stabilize the clot and bleeding will
occur later.
Inhibitors
Inhibitors are soluble plasma proteins that act as
natural anticoagulants; they prevent the initiation of
the clotting cascade. There are two major inhibitors in
plasma that keep the activation of coagulation under
control: the protease inhibitors and the protein C
pathway. The protease inhibitors inhibit coagulation
factors; they include antithrombin III, heparin cofactor,
tissue factor pathway inhibitor, and alpha 2 protease
inhibitor. The protein C pathway causes inactivation of
activated cofactors; these include protein C, its cofactor
of protein S, as well as activated protein C.
It is important for the coagulation laboratory to
communicate to the blood bank the type of reagent
that is used for coagulation studies and how it
performs. When a lot of reagent is received from a
manufacturer, it is assumed that a normal result
obtained on running the PT or APTT will correspond to
a normal amount of factor level reflecting about 50
percent of a factor level. Patients will do well with 30
to 40 percent of a factor level. Therefore, a normal PT
and APTT should minimally be able to reflect a 30 to 40
percent factor level. These screening test results are
Table 1. Guidelines for patient management: oral anticoagulation, target
range INR is 2 to 3
INR value Clinical risk Patient management
3.1 to 3.9 No bleeding Day 1: subtract 5–10% of total weekly
dose (TWD)
4.0 to 5.0 No bleeding Day 1: no warfarin, weekly reduce TWD
by 10–20%
5.1 to 9.0 No bleeding Hold warfarin, monitor INR until it
but at risk for reaches upper limit of therapeutic
bleeding range
Weekly: reduce TWD by 20–50%
Recheck INR in 72 hours
> 9.0 Significant risk Hold warfarin, give vitamin K, admit
for bleeding patient to hospital
Monitor INR until it reaches upper
therapeutic limit, reinstitute warfarin
Recheck INR until stable
>3.0 With bleeding Hold warfarin, give vitamin K by IV, give
plasma
Get hematology consult
Test INR 6–12 hours
Guidelines from New York-Presbyterian pharmacy.
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used by physicians to determine if a patient may bleed
in surgery. However, reagents can vary in the amount
and concentration of phospholipids. It is possible to
obtain a lot of reagents from a manufacturer that is
insensitive to certain factors. For example, a patient
sample is tested preoperatively with an APTT result of
34.5 seconds, the upper limit of the normal range is
35.4 seconds; therefore, the patient result is within the
normal range. The patient has a normal PT. The
information from these tests tells us that all factors in
the intrinsic, extrinsic, and common pathways appear
to be normal. The patient is cleared for surgery. During
the surgery the patient bleeds. There were no platelet
problems. The problem is that the reagent used to test
the APTT has a poor sensitivity to Factor IX, resulting in
the inability of the APTT to detect an abnormal Factor
IX level. It is important to understand how the reagent
performs, as illustrated in Table 2.
Having a basic understanding of how coagulation
testing works and its relation to blood bank outcomes
can improve the understanding of patient results by
both departments.
Donna D. Castellone, MS, MT(ASCP)SH, New York-
Presbyterian Hospital—Weill Cornell Medical Center,
New York City, New York.
Replacement Bodies 
The vacancies of medical technologists (MT) and
clinical laboratory scientists (CLS) in 2000 were
frightening to everyone; many presentations and
initiatives were implemented. The vacancy rate for MT
and CLS staff members was 14 percent in 2000 but,
since then, it has dropped to 4.3 percent according to
the 2003 wage and vacancy survey by the American
Society for Clinical Pathologists. The need for
replacement bodies in blood banking has been a
concern as the number of specialist in blood banking
(SBB) programs has diminished drastically since 1984.
The average age of MT and CLS staff members has been
estimated to be 51. The baby boomers are due to retire
and they will take with them the knowledge and love
of antibody identification. The question remains:What
is the blood bank community doing to educate and
encourage MT and CLS graduates to specialize in blood
bank technology?  The SBB programs have reviewed
this question and some have decided to try a distance
format for educating students. Currently there are six
programs offering distance education in blood
banking. The average number of people sitting for the
SBB ASCP exam is 125 each year, with less than 40
percent passing. For graduates of a Commission on
Accreditation of Allied Health Education Programs
(CAAHEP), the pass rate increases to 75 percent for
those passing the ASCP SBB exam. It was estimated
that 9000 MT and CLS graduates will be needed in the
year 2010. Currently, about 2000 people are taking the
MT ASCP examination each year. There will be a
shortage. For the first time ever, the workforce
includes four generations: those over 60 are working
alongside baby boomers as well as with Generation X
and Generation Y individuals.
What can be done for a better future?  At the
national level, organizations need to support education
and provide unity for the profession. At the hospital
and program level, more attention needs to be paid to
the needs of the Generation Y employees by looking at
flexible scheduling,clearly defined employee roles, and
rewarding achievements. As individuals, we need to
encourage young people to join the field, to be
mentors, and to be active in our organizations.
Shortages in MT and CLS staff members seem to be
looming on the horizon. New ways must be explored
to educate and to keep employees interested in the
field.
Janet Vincent, MS, SBB(ASCP), University of Texas
Medical Branch, Galveston, Texas.
Table 2. Relationship of factor level to APTT results






*normal range 24.3 to 35.4 sec.
†normal APTT, only 25% of factor; patient will bleed.
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